$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $3.0 million public offering. The offering consists of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant.

The company has granted underwriters a 45-day option to purchase up to an additional 102,272 shares. R.F. Lafferty & Co. is serving as the sole book-running manager. The offering, expected to close on September 5, 2025, is being made through a shelf registration statement previously filed with the SEC.

https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-pricing-of-3-0-million-public-kek9yvdma6w9.html